NXTC NextCure, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1661059 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY71.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-281.1%
ROA-166.2%
ROIC (approx.)-505.2%
Asset turnover—
Leverage & solvency
Liabilities / assets43.3%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio7.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $44.92M | $41.49M |
| SG&A expense | $12.69M | $15.72M |
| Operating income | -$57.62M | -$59.75M |
| Income tax | $0 | — |
| Net income | -$55.84M | -$55.65M |
| EBITDA | -$55.42M | -$56.85M |
| EPS (basic) | -19.65 | -23.88 |
| EPS (diluted) | -19.65 | -23.88 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 2.84M | 2.33M |
| Balance sheet | ||
| Cash & equivalents | $25.98M | $27.73M |
| Current assets | $43.75M | $71.81M |
| PP&E, net | $3.27M | $5.46M |
| Total assets | $50.18M | $80.86M |
| Current liabilities | $10.57M | $9.57M |
| Total liabilities | $15.24M | $15.39M |
| Shareholders' equity | $34.94M | $65.47M |
| Shares outstanding | 3.51M | 2.33M |
| Cash flow statement | ||
| Operating cash flow | -$49.61M | -$40.80M |
| Capital expenditure | — | $474,000 |
| Free cash flow | — | -$41.28M |
| Investing cash flow | $25.56M | $55.31M |
| Financing cash flow | $22.31M | $144,000 |
| Depreciation & amortization | $2.20M | $2.90M |
| Stock-based compensation | $2.99M | $6.33M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.